Dr. Daniel Drucker
Home > Researchers > Dr. Daniel Drucker
Dr. Daniel Drucker
Dr. Daniel J. Drucker
Dr. Daniel Drucker's
lab is internationally renowned not only for his
research, but as an environment where the clinical relevance of scientific breakthroughs is pursued.
lab has carried out basic science leading to the development of two new classes of therapies for the treatment of type 2 diabetes and a new therapy for patients with short bowel syndrome requiring parenteral nutrition.
research also shows tremendous promise for the treatment of obesity.
studies a family of hormones produced in the pancreas, gastrointestinal tract and brain.
Controlling blood glucose and insulin secretion, these hormones regulate our appetite, the absorption of nutrients from the food we eat, and the conversion of those nutrients to energy.
lab, Dr. Drucker
develops and/or characterizes analogues of pharmaceutical compositions that mimic and enhance the ability of these naturally occurring hormones to regulate these functions.
Since enhanced gut hormone action may be beneficial in diabetes, obesity and inflammatory bowel disorders, these analogues have real potential to lead to new and better treatments for diseases that afflict millions of people worldwide.
One discovery for example, has led to the development of two new drugs for the treatment of diabetes.
These drugs control blood glucose and insulin secretion without weight gain or hypoglycemia, common side effects of previous treatments for diabetes.
Another drug based on Dr. Drucker's research
is being clinically tested for the treatment of short bowel syndrome and Crohn's disease, and is simultaneously being tested as a therapy for other intestinal disorders.
There is also considerable evidence that other gut hormones could be developed into a drug that would induce a satiety signal and thus a treatment for obesity.
At a Glance
Dr. Dan Drucker is a clinician-scientist who develops treatments for diabetes, obesity, and intestinal disorders
studies a family of hormones produced in the pancreas, gastrointestinal tract and brain
In 2008, Dr. Drucker
reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection
lab has discovered two new treatments for type 2 diabetes and is working on a treatment for Crohn's disease
holds the Canada Research Chair in Regulatory Peptides; received the Prix Galien Canada Research Award 2008 for his
substantial contribution to the diagnosis, prevention or treatment of diseases; and the 2009 Clinical Investigator Award from The Endocrine Society